title: HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.
abstract: The partial efficacy of the recent HIV-1 vaccine trial in Thailand has rejuvenated the HIV vaccine field. There are now clear opportunities to dissect the potential correlates of protection against HIV-1. Comparisons of three major HIV-1 vaccine strategies used in human efficacy trials to date highlight a possible role for antibody-dependent cellular cytotoxicty (ADCC), rather than cytotoxic T lymphocyte or neutralizing antibody responses, in protective immunity. This review explores the HIV vaccine efficacy trials performed to date and the potential role for ADCC antibodies in assisting protective immunity.
authors.affiliation: Department of Microbiology and Immunology, University of Melbourne, Victoria, Australia.
authors.forename: Leia
authors.initials: L
authors.lastname: Wren
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Kent
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D013785:Thailand; D016896:Treatment Outcome
chemical_list: D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies